自體細胞療法市場－全球產業規模、佔有率、趨勢、機會和預測：來源、應用、終端用戶、地區和競爭格局（2021-2031年）

全球自體細胞療法市場預計將從 2025 年的 63.7 億美元成長到 2031 年的 89.8 億美元，複合年成長率為 5.89%。

這種治療方法包括採集、處理和重新輸注患者自身的細胞，以治療特定疾病，從而有效降低與異體移植相關的免疫排斥風險。推動該市場發展的關鍵因素是慢性疾病（尤其是腫瘤和自體免疫疾病）的盛行率不斷上升，這促使人們對個人化醫療干預的需求日益成長。此外，該領域還受益於有利的法規環境，加速了從臨床試驗到商業應用的轉化。例如，國際細胞與基因治療學會 (ISCT) 報告稱，美國食品藥物管理局(FDA) 在 2024 年核准了七種新的細胞和基因治療產品，凸顯了該領域創新和市場准入的快速發展。

儘管取得了這些積極進展，但自體細胞療法市場在生產擴充性和供應鏈複雜性方面仍面臨許多挑戰。這些治療方法的個人化特點要求進行嚴格的「靜脈到靜脈」移植流程，這既耗費人力又對物流要求極高。因此，高昂的生產成本仍然是一大挑戰，可能會阻礙自體細胞療法在全球醫療保健系統中的廣泛應用和推廣。

市場促進因素

全球癌症和自體免疫疾病的日益普及是自體細胞療法市場的主要驅動力，也使得人們迫切需要能夠治療疑難雜症的治療方法。隨著標準療法在多發性骨髓瘤等複雜疾病中的限制日益凸顯，對個人化細胞療法的需求呈指數級成長。日益加重的疾病負擔與治療方法的推廣應用和商業性化規模化直接相關。例如，根據傳奇生物於2025年3月發布的《2024年第四季及全年財務報告》，該公司自體CAR-T療法CarVicty全年銷售額達9.63億美元，並在全球範圍內治療了超過5000名患者。這表明，疑難腫瘤的診斷正在推動這些先進治療方法融入常規臨床實踐。

與此同時，CAR-T 和基因工程療法的監管核准數量激增，加速了市場的成熟。監管機構擴大核准早期療法領域的新型自主研發產品，這不僅證明了其安全性，也開闢了新的收入來源。這一發展勢頭體現在越來越多的核准治療方法進入商業市場。根據再生醫學聯盟 (Alliance for Regenerative Medicine) 2025 年 1 月發布的《產業趨勢簡報》，預計該領域在 2024 年將獲得 9 項監管核准，標誌著從臨床開發到市場交付的強勁轉型。監管方面的成功正在推動快速的財務成長。正如百時美施貴寶 (Bristol-Myers Squibb) 2025 年 2 月的報告顯示，其細胞療法 Braiange 的全球銷售額達到 7.47 億美元，年成長 105%。

市場挑戰

高昂的製造成本，主要源自於產能有限和供應鏈複雜，嚴重阻礙了全球自體細胞療法市場的成長。與傳統藥物和異體療法不同，自體細胞療法依賴患者自身的細胞，因此每劑藥物都需要客製化的、勞力密集的生產流程。這種缺乏標準化的現狀使得該行業無法實現規模經濟，導致產品售價居高不下，進而造成全球醫療體系報銷範圍有限，患者獲取治療的機會也受到限制。

隨著在研治療方法的增加，生產瓶頸問題日益嚴峻。根據國際細胞與基因治療學會（ISCT）預測，到2024年，全球在研治療方法數量將增至3063種，光上半年就增加了7.5%。臨床候選藥物的快速累積給本已不堪重負的生產基礎設施帶來了巨大壓力。如果無法有效擴大生產規模以滿足不斷成長的需求，市場將面臨「商業化瓶頸」——即創新治療方法核准後，卻無法以合理的價格或充足的供應量推向市場。

市場趨勢

自體CAR-T療法在自體免疫疾病領域的拓展標誌著市場格局的根本性轉變。其應用範圍已從腫瘤學擴展到全身性紅斑性狼瘡和多發性硬化症等嚴重的治療。研發人員正利用基因工程改造的T細胞顯著清除B細胞並重置免疫系統的能力，為對標準免疫抑制劑抗藥性的患者帶來功能性治癒的可能性。這種日益成長的臨床關注正在迅速建立一個強大的開發平臺，從而降低對癌症治療的依賴。例如，2024年7月發表在Medscape上的報導《CAR-T細胞在自體免疫疾病中的研究蓬勃發展》報導了約40項正在進行的、利用CAR-T細胞治療各種自體免疫疾病的研究，這顯著地顯示了資源正向這一新興治療領域轉移。

同時，腫瘤浸潤淋巴細胞（TIL）療法的商業化代表著固態腫瘤領域的重大突破，有效地將目標市場拓展至骨髓惡性腫瘤之外。這一趨勢涉及採集和激活患者特異性免疫細胞，以標靶治療傳統上難以用細胞療法治療的疾病領域（例如轉移性黑色素瘤）中複雜的腫瘤微環境。這些新型療法迅速獲得市場關注，也印證了其商業性可行性。根據Iovance Biotherapeutics公司於2024年11月發布的“2024年第三季度及全年財務業績”，該公司TIL療法Amtagvi在第三季度於美國創造了4210萬美元的淨產品收入，展現了固體癌細胞療法強勁的發展勢頭。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球自體細胞療法市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依來源（骨髓、表皮、間質幹細胞、造血幹細胞、軟骨細胞、其他）
  • 依應用領域（癌症、神經退化性疾病、心血管疾病、自體免疫疾病、整形外科、創傷治療等）
  • 按最終使用者（醫院/診所、門診中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美自體細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲自體細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區自體細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲自體細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲自體細胞療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球自體細胞療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Biomatrica, Inc.
• Holostem Terapie Avanzate SRL
• Pharmicell Co. Inc
• Caladrius Biosciences Inc
• US Stem Cell Inc
• Bristol Myers Squibb Company
• Corning Incorporated
• Vericel Corporation
• Catalent, Inc
• Sartorius AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Autologous Cell Therapy Market is projected to expand from USD 6.37 Billion in 2025 to USD 8.98 Billion by 2031, reflecting a compound annual growth rate of 5.89%. This therapeutic approach involves the collection, processing, and reintroduction of a patient's own cells to address specific medical conditions, effectively mitigating the immune rejection risks often associated with allogeneic alternatives. A primary catalyst for this market is the increasing prevalence of chronic diseases, specifically oncology and autoimmune disorders, which has heightened the demand for personalized medical interventions. Furthermore, the sector benefits from a supportive regulatory environment that accelerates the transition of therapies from clinical trials to commercial availability; for example, the International Society for Cell & Gene Therapy reported in 2024 that the United States Food and Drug Administration approved seven new cell and gene therapy products, highlighting the rapid pace of innovation and market entry.

Despite these positive developments, the market encounters significant hurdles regarding production scalability and supply chain complexity. The personalized nature of these treatments necessitates a rigorous "vein-to-vein" process that is both labor-intensive and logistically demanding. Consequently, high manufacturing costs remain a substantial challenge, potentially hindering the widespread adoption and expansion of autologous cell therapies across global healthcare systems.

Market Driver

The rising global prevalence of cancer and autoimmune disorders acts as the primary engine for the autologous cell therapy market, creating an urgent need for treatments capable of addressing refractory conditions. As the limitations of standard care become evident in complex indications such as multiple myeloma, the demand for personalized cellular interventions is increasing sharply. This growing disease burden is translating directly into significant therapy adoption and commercial volume; for instance, Legend Biotech's "Fourth Quarter and Full Year 2024 Financial Results" in March 2025 reported that its autologous CAR-T therapy, Carvykti, generated $963 million in full-year sales and treated over 5,000 patients globally, demonstrating how persistent oncological diagnoses are driving the integration of these advanced modalities into routine clinical practice.

Simultaneously, a surge in regulatory approvals for CAR-T and gene-modified therapies is accelerating market maturity. Regulatory bodies are increasingly clearing novel autologous products for earlier lines of therapy, thereby validating their safety profiles and opening new revenue streams. This momentum is reflected in the growing volume of approved therapies entering the commercial space; according to the Alliance for Regenerative Medicine's "State of the Industry Briefing" in January 2025, the sector secured nine regulatory approvals in 2024, signaling a robust shift from clinical development to market availability. This regulatory success is fueling rapid financial growth, as evidenced by Bristol Myers Squibb's February 2025 report, which noted that global revenue for its cell therapy Breyanzi reached $747 million, marking a 105% increase compared to the previous year.

Market Challenge

The high cost of manufacturing, driven by limited scalability and supply chain complexity, presents a formidable barrier to the growth of the Global Autologous Cell Therapy Market. Unlike traditional pharmaceutical or allogeneic treatments, autologous therapies rely on a patient's own cells, necessitating a bespoke, labor-intensive manufacturing process for each individual dose. This lack of standardization prevents the industry from achieving economies of scale, resulting in exorbitant costs of goods sold that restrict reimbursement potential and limit patient access within global healthcare systems.

This production bottleneck is becoming increasingly critical as the volume of developing treatments grows. According to the International Society for Cell & Gene Therapy, the global pipeline expanded in 2024 to include 3,063 active therapies, representing a 7.5 percent increase in the first half of the year alone. This rapid accumulation of clinical candidates places immense pressure on an already strained manufacturing infrastructure. Without the capacity to efficiently scale production to meet this rising demand, the market faces a "commercialization bottleneck" where innovative therapies are approved but cannot be delivered at a viable price point or volume.

Market Trends

The expansion of autologous CAR-T therapies into autoimmune indications marks a fundamental market pivot, extending beyond oncology to treat severe conditions such as systemic lupus erythematosus and multiple sclerosis. Developers are harnessing the ability of engineered T-cells to deeply deplete B-cells and reset the immune system, offering a potential functional cure for patients refractory to standard immunosuppressants. This intensifying clinical focus is rapidly building a robust development pipeline that diversifies the sector's reliance on cancer treatments; for example, a July 2024 Medscape article titled "CAR T-Cell Studies in Autoimmune Diseases Are Proliferating" noted approximately 40 active studies utilizing CAR-T cells across various autoimmune indications, reflecting a significant resource shift toward this new therapeutic frontier.

Concurrently, the commercialization of Tumor-Infiltrating Lymphocyte (TIL) therapies represents a critical breakthrough in the solid tumor segment, effectively widening the addressable market beyond hematological malignancies. This trend involves extracting and invigorating patient-specific immune cells to target complex cancer microenvironments in indications like metastatic melanoma, which have historically been difficult to treat with cellular modalities. The immediate market traction of these novel therapies underscores their commercial viability; according to Iovance Biotherapeutics' "Third Quarter and Year to Date 2024 Financial Results" from November 2024, the company's TIL therapy Amtagvi generated $42.1 million in U.S. net product revenue during the third quarter, signaling a strong adoption trajectory for solid tumor cell therapies.

Key Market Players

• Biomatrica, Inc.
• Holostem Terapie Avanzate S.R.L
• Pharmicell Co. Inc
• Caladrius Biosciences Inc
• U.S. Stem Cell Inc
• Bristol Myers Squibb Company
• Corning Incorporated
• Vericel Corporation
• Catalent, Inc
• Sartorius AG

Report Scope

In this report, the Global Autologous Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autologous Cell Therapy Market, By Source

• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Haematopoietic Stem Cells
• Chondrocytes
• Others

Autologous Cell Therapy Market, By Application

• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Orthopedics
• Wound Healing
• Others

Autologous Cell Therapy Market, By End User

• Hospitals & Clinics
• Ambulatory Centers
• Others

Autologous Cell Therapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autologous Cell Therapy Market.

Available Customizations:

Global Autologous Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Autologous Cell Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Bone Marrow, Epidermis, Mesenchymal Stem Cells, Haematopoietic Stem Cells, Chondrocytes, Others)
  • 5.2.2. By Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Autologous Cell Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Autologous Cell Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Autologous Cell Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Autologous Cell Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Autologous Cell Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Autologous Cell Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Autologous Cell Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Autologous Cell Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Autologous Cell Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Autologous Cell Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Autologous Cell Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Autologous Cell Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Autologous Cell Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Autologous Cell Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Autologous Cell Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Autologous Cell Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Autologous Cell Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Autologous Cell Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Autologous Cell Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Autologous Cell Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Autologous Cell Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Autologous Cell Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Autologous Cell Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Autologous Cell Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Autologous Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Biomatrica, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Holostem Terapie Avanzate S.R.L
• 15.3. Pharmicell Co. Inc
• 15.4. Caladrius Biosciences Inc
• 15.5. U.S. Stem Cell Inc
• 15.6. Bristol Myers Squibb Company
• 15.7. Corning Incorporated
• 15.8. Vericel Corporation
• 15.9. Catalent, Inc
• 15.10. Sartorius AG

16. Strategic Recommendations

17. About Us & Disclaimer